Prescription Medicines
Recipram Tab.
- Product Category
- New SSRI antidepressants
- Active Ingredients
- Escitalopram oxalate
- Appearance
- A white rectangular shape with a dividing line and S and C engraved on one side and 10 engraved on the other side.
- Reimbursement Code
- 648102570
01 / 02
1. Composition and Strength
- Active ingredient: Escitalopram oxalate (USP) ---- 12.77mg (10mg as escitalopram)
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: titanium oxide, magnesium stearate, low-substituted hydroxypropyl cellulose, colloidal silicon dioxide, polyethylene glycol 6000, hydroxypropyl cellulose, hypromellose 2910
2. Effectiveness
Treatment of major depressive disorder, panic disorder with or without agoraphobia, social anxiety disorder (social phobia), generalized anxiety disorder, and obsessive-compulsive disorder.
3. Dosage and dosage
The safety of doses exceeding 20 mg per day has not been established.
This medication is administered once a day in the morning or evening, regardless of meal.
1) Adult
(1) Major depressive disorder:
The usual dose is 10 mg once a day. Depending on the patient's response, the dose can be increased up to 20 mg per day. If you wish to increase the dose of this drug to 20mg, the increase must be done at intervals of at least 1 week.
Typically, it takes 2-4 weeks for antidepressants to take effect. Even after symptoms disappear, at least 6 months of drug treatment is necessary to ensure treatment effectiveness.
(2) Panic disorder with or without agoraphobia:
It is recommended to administer an initial dose of 5 mg per day for 1 week and then increase the dose to 10 mg per day. Depending on the patient's response, the dose can be increased up to 20 mg per day.
The maximum effect appears after about 3 months. The safety and effectiveness of long-term administration of this drug for more than 10 weeks in the treatment of panic disorder have not been systematically studied. Physicians should periodically reassess each patient to determine the need for ongoing treatment.
(3) Social anxiety disorder:
The usual dose is 10 mg once a day. Generally, 2-4 weeks are needed for symptoms to improve. After that, depending on the patient's response, the dose can be reduced to 5 mg per day or increased to a maximum of 20 mg per day.
Social anxiety disorder is a disease with a chronic course, and it is recommended to continue treatment for 12 weeks to ensure treatment effectiveness. Long-term treatment for responding patients has been studied for 6 months and is considered on an individual patient basis to prevent recurrence. The usefulness of long-term treatment should be reassessed regularly.
Social anxiety disorder is a well-defined diagnostic term for a specific disorder and should not be confused with excessive shyness. Drug treatment is administered only when social anxiety disorder significantly interferes with occupational and social activities. Comparison of pharmacological treatment with cognitive behavioral therapy has not been evaluated. Pharmacological treatment is one part of an overall treatment strategy.
(4) Generalized anxiety disorder:
The initial dose is 10 mg once a day. Depending on the patient's response, the dose may be increased up to 20 mg per day after administration for at least 1 week.
A long-term dosing trial was conducted in patients who responded to open administration for 12 weeks, administering 20 mg per day for at least 6 months. Physicians should periodically reassess the usefulness of long-term treatment with this drug for each patient.
(5) Obsessive-compulsive disorder:
The usual dose is 10 mg once a day. Depending on the patient's response, the dose can be increased to a maximum of 20 mg per day.
A long-term dosing trial was conducted in patients who responded to 16 weeks of open-label administration, administering 10 mg or 20 mg per day for at least 24 weeks. Since obsessive-compulsive disorder is a chronic disease, it must be administered for a sufficient period of time to ensure recovery of symptoms, and when this drug is administered long-term, the usefulness and dosage for each patient are regularly reevaluated.
2) Patients with renal impairment
No dose adjustment is necessary in patients with mild to moderate renal impairment. Caution should be exercised in patients with severe renal impairment (CLCR < 30 mL/min).
3) Patients with liver impairment
It is recommended to administer an initial dose of 5 mg per day for the first two weeks. Depending on the patient's response, the dosage can be increased up to 10 mg per day.
4) Discontinuation of administration
When discontinuing this medication, the dose should be tapered gradually over at least 1-2 weeks to avoid the possibility of withdrawal symptoms.
5) Related to switching to MAO inhibitors to treat mental illness
When discontinuing treatment with an MAO inhibitor for the treatment of mental illness and starting treatment with the same drug, there must be an interval of at least 14 days. Conversely, before starting treatment with an MAO inhibitor for the treatment of mental illness, at least 14 days must elapse after stopping the drug.
6) Other MAO inhibitors such as linezolid or methylene blue
Patients receiving linezolid or intravenous methylene blue products should not begin treatment with these products due to the increased risk of serotonin syndrome. Administration should be considered in patients requiring hospitalization, other interventional procedures, or treatment of more urgent psychiatric conditions.
There may be a need to urgently administer linezolid or intravenous methylene blue to patients who are already receiving this medication. If there is no alternative drug to linezolid or intravenous methylene blue and the benefit of treatment with linezolid or intravenous methylene blue is judged to outweigh the risk of serotonin syndrome in a specific patient, the medication should be discontinued immediately and linezolid or intravenous methylene blue should be administered immediately. The preparation can be administered. Patients should be monitored for symptoms of serotonin syndrome for 2 weeks after receiving linezolid or intravenous methylene blue products or 24 hours after the last dose, whichever comes first. Treatment with linezolid or intravenous methylene blue can be restarted 24 hours after the last dose.
The risk of administering methylene blue preparation non-intravenously (oral tablet or local injection) or injecting less than 1 mg/kg intravenously is not clear. Nevertheless, clinicians should be aware of the potential for emergent symptoms of serotonin syndrome with this use.
4. Precautions for use
1. Warning
Suicidality and antidepressants
Short-term studies of children, adolescents, and young adults (ages 18 to 24) with major depression or other psychiatric disorders have reported that antidepressants increase the risk of suicidal thoughts and behaviors (suicidality) compared to placebo. Physicians considering administering this drug or other antidepressants to children, adolescents, or young adults should always carefully consider whether the clinical need outweighs the risks. In short-term studies, antidepressants did not increase the risk of suicidality compared with placebo in adults over 25 years of age, and this risk was reduced with antidepressants compared to placebo in adults over 65 years of age. Depression and other psychiatric disorders themselves are associated with an increased risk of suicide. Patients of any age starting treatment with antidepressants should be appropriately monitored and carefully observed for worsening disease, suicidal tendencies, or changes in other abnormal behaviors such as hostility, aggression, or anger. The patient's family or guardian is also instructed to observe the patient carefully and contact the doctor if necessary. This drug is not approved for use in children and adolescents.
2. Do not administer to the following patients
1) Patients with hypersensitivity to escitalopram, the main ingredient of this drug, citalopram, a racemic form, or other components of this drug
2) Patients taking MAO inhibitors
Co-administration of this drug and MAO inhibitors for the treatment of mental illness or administration of MAO inhibitors within 14 days of discontinuing treatment with this drug is contraindicated because it increases the risk of serotonin syndrome. It is also contraindicated to administer this drug within 14 days of discontinuing treatment with MAO inhibitors for the treatment of mental illness. (Refer to section 4. Usage/Dosage and section 4. General precautions)
Initiating this drug in patients receiving MAO inhibitors such as linezolid or intravenous methylene blue preparations is also contraindicated due to the increased risk of serotonin syndrome (see Dosage and Administration section and Section 4. General Precautions).
3) Patients taking pimozide
4) Patients known to have congenital long QT syndrome or QT interval prolongation
5) Patients taking drugs that cause QT interval prolongation
3. Administer with caution to the following patients:
1) Patients with closed-angle glaucoma or patients with a history of glaucoma: Selective serotonin reuptake inhibitors (SSRIs), including this drug, may affect pupil size and cause mydriasis. This mydriatic effect narrows the canthus, increases intraocular pressure, and has the potential to cause closed-angle glaucoma, especially in patients with a predisposition to the disease. Therefore, patients with closed-angle glaucoma or patients with a history of glaucoma should use this drug with caution.
4. Adverse reactions
Adverse reactions occurred most frequently in the first 1-2 weeks after starting treatment with this drug, and generally decreased in intensity and frequency as treatment continued.
1) Adverse reactions known from SSRI drugs and observed in placebo-controlled clinical trials or post-marketing spontaneous reports of this drug are summarized by organ system and frequency in the table below.
Incidence rates are results obtained from clinical trials and are not placebo-corrected values. Incidence is defined as: very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥ 1/1000 to ≤ 1/100), rare (≥ 1/10000 to ≤ 1/1000), very rare (≤ 1/10000), or unknown (given data). (not measurable)
-Refer to attached document table-
2) The following are adverse reactions that occur with SSRI drugs: Increased suicidal tendencies in children, adolescents, and young adults (18-24 years old).
3) After marketing, ventricular arrhythmias including QT interval prolongation and polymorphic ventricular tachycardia (torsade de pointes) were reported, mainly in women, hypokalemia, and patients with existing QT interval prolongation or heart disease.
4) In an epidemiological study mainly targeting patients over 50 years of age, it was found that the risk of fracture increased in patients taking SSRIs and TCAs.
5) As a result of the post-marketing use results survey conducted in Korea for 4 years, the case rate of adverse reactions was reported to be 4.39% (60 cases/1,368 cases) regardless of causal relationship. ‘Nausea’ and ‘headache’ were the most common at 0.37% (5/1,368 people, 5 cases), ‘constipation’ and ‘dizziness’ at 0.29% (4/1,368 people, 4 cases), ‘dry mouth’, ‘abdominal pain’, ‘insomnia’, and ‘weight gain’ at 0.22% (3/1,368 people, 3 cases). ‘Fever’, ‘vomiting’, ‘indigestion’, ‘enteritis’, paresthesia’, ‘cough’, ‘sexual dysfunction’, ‘palpitations’ were 0.15% (2/1,368 people, 2 cases), other ‘diarrhea’, ‘paralysis’, ‘extrapyramidal disorder’, ‘migraine’, ‘reduced libido’, ‘lack of appetite’, ‘hallucinations’, ‘asthma’, ‘Difficult breathing’, ‘fracture’, ‘joint pain’, and ‘hypertension’ were each reported at 0.07% (1/1,368 people, 1 case). Among them, the rate of adverse drug reactions was 0.80% (11/1,368 people, 12 cases), 'nausea' at 0.22% (3/1,368 people, 3 cases), 'abdominal pain', 'drowsiness', and 'sexual dysfunction' at 0.15% each (2/1,368 people, 2 cases), and 'dizziness', 'reduced libido', ‘Weight gain’ was reported in 0.07% (1/1,368 people, 1 case).
Reported adverse reactions are classified by institution as follows.
① Gastrointestinal system: nausea, constipation, dry mouth, abdominal pain, vomiting, indigestion, enteritis, diarrhea
② Central and peripheral nervous system: headache, dizziness, paresthesia, paralysis, extrapyramidal disorder, migraine
③ Mental nervous system: drowsiness, insomnia, aggressive reactions, decreased libido, loss of appetite, hallucinations
④ Respiratory system: cough, asthma, difficulty breathing
⑤ Metabolic and nutritional abnormalities: weight gain
⑥ Systemic abnormalities: chest pain, fever
⑦ Musculoskeletal system: fractures, joint pain
⑧ Reproductive system (male): Sexual dysfunction
⑨ Cardiovascular system: palpitations, high blood pressure
6) In Korea, there were 88 adverse reactions reported separately from the post-marketing use results survey in 80 patients, including 15 nausea, 14 headaches, 9 dizziness, 8 drowsiness, 6 gastrointestinal disorders, 5 heartburn, 4 sedation, dry mouth, decreased libido, 3 each for decreased appetite, dry mouth, indigestion, sweating, frequent urination, sexual dysfunction, tremors, and weight gain. Two cases and one case each of abdominal discomfort, anxiety, insomnia, and visual hallucinations were reported. Among these, headache and frequent urination were unexpected side effects.
5. General precautions
The following precautions apply to all SSRI (Selective Serotonin Re-uptake Inhibitors) antidepressants.
1) Retrograde anxiety
Some patients with panic disorder may experience an increase in anxiety symptoms early in the initiation of antidepressant medication. This retrograde reaction usually disappears within the first two weeks of starting treatment. It is recommended to begin treatment with a lower initial dose to reduce the likelihood of developing anxiety.
2) Epileptic seizures
This drug should be discontinued in patients who experience epileptic seizures for the first time or if the number of seizures increases (in patients previously diagnosed with epilepsy). SSRIs should not be administered to patients with unstable epilepsy, and patients with controllable epilepsy should be closely observed after administration.
3) mania
SSRIs should be used with caution in patients with a history of mania/hypomania. In patients who are active in a manic state, administration of SSRIs should be discontinued.
Although not proven in controlled clinical trials, the use of antidepressants during a depressive episode in patients with bipolar disorder may precipitate mania or manic episodes. Therefore, before administering antidepressants, a detailed psychiatric history, including family history of suicide, bipolar disorder, or depression, should be checked to screen for the possibility of bipolar disorder.
4) Diabetes
When SSRIs are administered to patients with diabetes, glycemic control may be altered. Dosages of insulin and oral hypoglycemic agents may need to be adjusted.
5) Suicide
(1) Patients (adults, children) with major depression may experience worsening of depressive symptoms, suicidal thoughts and behaviors (suicidality), and abnormal behavioral changes even if they are taking antidepressants, until the disease shows significant improvement.
(2) Suicide is a known risk factor for depression and certain other psychiatric disorders, and these disorders are themselves the strongest predictors of suicide. However, there has been long-standing concern that antidepressants may lead to worsening of depressive symptoms and the development of suicidality in some patients during the early stages of treatment. A pooled analysis of placebo-controlled, short-term clinical trials of antidepressants (SSRIs and others) indicates that these drugs increase the risk of suicidal thoughts and behaviors (suicidality) in children, adolescents, and young adults (18-24 years) with major depression and other psychiatric disorders. In short-term studies, antidepressants did not increase the risk of suicidality compared with placebo in adults over 25 years of age. In adults over 65 years of age, this risk was reduced with antidepressants compared to placebo.
(3) A pooled analysis of placebo-controlled clinical trials in children and adolescents with major depression, obsessive-compulsive disorder, or other psychiatric disorders included a total of 24 short-term clinical trials of 9 antidepressants in more than 4,400 patients. The pooled analysis of placebo-controlled clinical trials in adults with major depression and other psychiatric disorders included a total of 295 short-term (median duration: 2 months) clinical trials of 11 antidepressants in more than 77,000 patients. Although there were significant differences in the risk of suicidality among drugs, there was a tendency for most all drugs studied to increase suicidality in young adults. There was a difference in the absolute risk of suicidality among different indications, with the highest incidence in major depression. However, the difference in risk (antidepressants vs. placebo) was relatively stable within age groups and between indications. This risk difference (difference between antidepressants and placebo in the number of suicidal tendencies per 1,000 treated patients) is shown in Table 1 below.
-Refer to attached document table-
(4) Suicide did not occur in any pediatric clinical trials. Suicides occurred in clinical trials in adults, but the numbers were not sufficient to draw any conclusions about the drug's effect on suicide. It is not known whether the risk of suicidality extends to long-term (i.e., more than several months) use of the drug. However, there is ample evidence from ongoing placebo-controlled clinical trials in adults with depression that the use of antidepressants may delay the recurrence of depression.
(5) It is unknown whether there is an increase in suicidal tendencies in adults or in patients taking long-term medication for several months or more; however, patients using antidepressants should be carefully monitored for the appearance and/or worsening of suicidal tendencies, self-harm, hostility, etc. during the first few months of administration or when changing the dose (increase or decrease).
(6) Patients using antidepressants may experience anxiety, agitation, panic disorder, insomnia, excitement, hostility, aggression, impulsivity, akathisia, hypomania, and mania. Although the correlation with these symptoms is unclear, caution should be exercised as they may be precursors to the development of suicidal tendencies. In addition, instruct family members and guardians to monitor these symptoms, suicidal tendencies, and clinical deterioration on a daily basis and notify the doctor immediately when symptoms appear.
(7) If depressive symptoms continue to worsen, suicidal tendencies appear, or symptoms that may be prodromal symptoms of suicidal tendencies (severe or sudden symptoms, symptoms not originally present in the patient) appear, discontinuation of this drug should be considered.
(8) When treating patients with other mental illnesses, the same precautions should be taken as when treating patients with major depression.
(9) Patients who have a history of suicide-related events or who have significant suicidal ideation before the start of administration are at greater risk of suicidal thoughts or attempts and should be carefully monitored during the administration period.
6) Akathisia/psychomotor anxiety
Administration of SSRIs/SNRIs is associated with the development of akathisia, a condition characterized by discomfort and anxiety and an inability to sit or stand still and an occasional need to move, which occurs within the first few weeks of administration. Increasing the dose in patients experiencing these symptoms may be harmful.
7) Hyponatremia
Hyponatremia, usually due to syndrome of abnormal secretion of antidiuretic hormone (SIADH), has been reported rarely with the use of SSRIs, and generally resolved with discontinuation of drug administration. Caution should be exercised in high-risk patients such as the elderly, patients with liver cirrhosis, or patients taking concomitant medications that may cause hyponatremia.
8) Bleeding
Skin bleeding abnormalities such as ecchymosis and purpura have been reported due to SSRIs. SSRIs or SNRIs may increase the risk of postpartum hemorrhage (see section ‘7. Administration to pregnant and lactating women’). Caution should be exercised, especially when administering SSRIs to patients taking oral anticoagulants or drugs known to affect platelet function (e.g. atypical antipsychotics, phenothiazines, most tricyclic antidepressants, acetosalicylic acid, nonsteroidal anti-inflammatory drugs (NSAIDs), ticlopidine, dipyridamole) or to patients with a known bleeding tendency.
9) Electroconvulsive Therapy
Caution should be exercised because experience with the combined treatment of SSRIs and electroconvulsive therapy is limited.
10) Cardiovascular disease
Because there is insufficient clinical experience, caution should be exercised in patients with coronary vascular disease.
11) Serotonin Syndrome
Serotonin-norepinephrine reuptake inhibitors (SNRIs) and serotonin selective reuptake inhibitors (SSRIs), including these agents, were administered alone, as well as other serotonergic drugs [triptan class drugs (sumatriptan, etc.), tricyclic antidepressants, opiates (fentanyl, etc.), lithium, tramadol, tryptophan, buspirone, and St. John's wort (St. John's wort). The development of potentially life-threatening serotonin syndrome has been reported when co-administered with drugs that inhibit serotonin metabolism (especially MAO inhibitors, both for the treatment of mental disorders, and other drugs such as linezolid and intravenous methylene blue).
Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, coma), autonomic instability (e.g., tachycardia, unstable blood pressure, dizziness, sweating, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, twitching, myoclonus, hyperreflexia, dyscoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome.
Co-administration of this agent and MAO inhibitors for the treatment of mental disorders is contraindicated. Additionally, treatment with MAO inhibitors such as linezolid or intravenous methylene blue should not be initiated in patients receiving MAO inhibitors. All postmarketing reports of methylene blue products for which route of administration information was provided include intravenous administration with a dose range of 1 mg/kg to 8 mg/kg. The reports do not include cases where methylene blue was administered by other routes of administration (such as tablets or local injection) or in low doses. Patients receiving this medication may need to start treatment with MAO inhibitors such as linezolid or intravenous methylene blue. This agent should be discontinued before starting MAO inhibitor treatment. (Refer to Dosage/Dosage section and section 2. Do not administer to the following patients)
If there is clinical benefit in co-administering this agent with other serotonergic drugs, for example triptans (e.g. sumatriptan), tricyclic antidepressants, opiates (e.g. fentanyl), lithium, tramadol, buspirone, tryptophan, and St. John's Wort, patients should be aware of the potentially increased risk of serotonin syndrome, especially during treatment initiation and when increasing doses. must be recognized
If the above-mentioned adverse reactions occur when co-administering this agent and serotonergic drugs, administration should be discontinued immediately and supportive symptomatic treatment should be initiated.
12) Withdrawal symptoms
Because there is a risk of experiencing withdrawal symptoms such as dizziness, sleep disturbance, and anxiety due to sudden discontinuation of administration, patients or guardians should not unilaterally stop taking this drug without consulting the prescribing doctor. When discontinuing treatment with this drug, it is recommended to gradually reduce the dose over several weeks or months.
Withdrawal symptoms due to discontinuation of treatment, especially sudden discontinuation of treatment, are frequent. In clinical trials, adverse reactions occurred when treatment was discontinued in approximately 25% of patients treated with this drug and in approximately 15% of patients treated with placebo.
The risk of withdrawal symptoms depends on several factors, including the duration and dose of treatment and the rate of dose reduction. The most commonly reported adverse reactions were dizziness, paresthesia (including paresthesia and electric shock sensations), sleep disturbances (insomnia and violent dreams), nervousness or anxiety, nausea and/or vomiting, tremors, confusion, sweating, headache, diarrhea, palpitations, agitation, irritability, and visual disturbances. In most cases, these symptoms are mild to moderate, but in some patients they can be severe.
These adverse reactions usually occur within the first few days after discontinuation of treatment, but very rarely have such symptoms been reported in patients who inadvertently missed a single dose. Generally, these symptoms are self-limited and usually resolve within 2 weeks, but in some patients they may be prolonged (2-3 months or longer).
13) QT interval prolongation
This drug has been shown to cause QT interval prolongation in a dose-dependent manner. After marketing, ventricular arrhythmias, including QT interval prolongation and polymorphic ventricular tachycardia (torsade de pointes), have been reported, mainly in women, hypokalemia, and patients with pre-existing QT interval prolongation or cardiac disease. Caution should be exercised in patients with significant bradycardia or patients who have recently had acute myocardial infarction or decompensated heart failure. Electrolyte imbalances such as hypokalemia and hypomagnesemia increase the risk of malignant arrhythmias and should be controlled prior to administration of this drug. If the patient is receiving treatment for cardiac disease, an ECG review should be considered before starting treatment with this drug. If there are signs of cardiac arrhythmia while taking this drug, treatment should be discontinued and an ECG should be performed.
14) Sexual dysfunction: Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) can cause symptoms of sexual dysfunction. Persistent sexual dysfunction with symptoms persisting even after discontinuation of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) has been reported.
6. Interaction
1) Pharmacokinetic interactions
(1) Contraindications for combined use:
① Non-selective, irreversible MAO inhibitor
In patients receiving SSRI drugs in combination with non-selective, irreversible MAO inhibitors or who recently stopped taking SSRIs and started taking MAO inhibitors, serious and sometimes fatal adverse reactions have been reported, including high fever, twitching, myoclonus, autonomic anxiety due to rapid fluctuations in vital signs, delirium, and changes in mental status, including extreme agitation that may progress to coma. Additionally, serotonin syndrome occurred in some patients.
Therefore, this drug and non-selective, irreversible MAO inhibitors should not be administered together. In the case of irreversible MAO inhibitors, start treatment 14 days after stopping treatment. Administration of non-selective, irreversible MAO inhibitors should be started at least 14 days after discontinuation of this drug.
② Reversible, non-selective MAO-inhibitor
Linezolid, an antibiotic, is a reversible non-selective MAO-inhibitor and should not be administered in combination with this drug. If co-administration is necessary, the lowest recommended dose should be administered and careful clinical observation should be conducted.
③ Reversible, selective MAO-A inhibitor
Due to the risk of serotonin syndrome, concurrent use of this drug with MAO-A inhibitors such as moclobemide is not recommended. If coadministration is necessary, administration should be initiated at the lowest recommended dose and careful clinical observation should be conducted.
④ Irreversible, selective MAO-B inhibitor
Concomitant use with selegiline should be used cautiously due to the risk of serotonin syndrome. A daily dose of 10 mg selegiline was safe when administered in combination with racemic citalopram.
⑤ Pimozide
In patients who were administered racemic citalopram 40 mg/day for 11 days, when single-dose pimozide 2 mg was co-administered, the AUC and Cmax of pimozide increased, although not consistently during the test period. Co-administration of pimozide and citalopram increased the QTc interval by approximately 10 msec. Due to the interaction seen with low doses of pimozide, this drug and pimozide should not be administered together.
⑥ Prolongation of QT interval
Although pharmacokinetic and pharmacodynamic studies have not been conducted on co-administration of this drug with other drugs that prolong the QT interval, additive effects of this drug cannot be excluded. Therefore, classes IA and III antiarrhythmic drugs, antipsychotics (e.g. phenothiazine derivatives, pimozide, haloperidol), tricyclic antidepressants, certain antibiotics (e.g. sparfloxacin, moxifloxacin, erythromycin IV, pentamidine, antimalarials (especially halofantrine)), certain antihistamines (astemizole, mizolastine), etc. Do not co-administer this drug with drugs that prolong the interval.
(2) Co-administration with caution
① Serotonergic drugs: Co-administration with serotonergic drugs (e.g. tramadol, sumatriptan and other triptan drugs) may cause serotonin syndrome.
② Drugs that lower the epileptic seizure threshold: SSRIs can lower the seizure threshold. Caution should be exercised when coadministering with other drugs that may lower the seizure threshold (antidepressants (tricyclics, SSRIs), neuroleptics (phenothiazines, butyrophenones, thioxanthenes), meproquine, bupropion, tramadol).
③ Lithium, tryptophan: There are reports that the effect of SSRIs is increased when administered in combination with lithium or tryptophan, so caution should be exercised when administering these drugs and SSRIs together.
④St. St. John's Wort: SSRIs and St. John's Wort. When coadministered with herbal preparations containing St. John's Wort (Hypericum perforatum), the occurrence of adverse reactions may increase.
⑤ Bleeding: If this drug and oral anticoagulants are administered together, the anticoagulant effect may be affected. In patients taking oral anticoagulants, the anticoagulant effect should be carefully monitored when starting or discontinuing treatment with this drug. Concomitant use with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase bleeding tendency.
⑥ Alcohol: No pharmacokinetic or pharmacodynamic interaction is expected between this drug and alcohol. However, like other psychoactive drugs, this drug is not recommended to be used together with alcohol.
2) Pharmacokinetic interactions
(1) The effect of other drugs on the pharmacokinetics of this drug
This drug is primarily metabolized by CYP2C19. CYP3A4 and CYP2D6 may also be involved in the metabolism of this drug, but to a very minor extent. A portion of the drug's main metabolite, demethylated escitalopram (S-DCT), appears to be re-metabolized by CYP2D6.
Co-administration of this drug with omeprazole (CYP2C19 inhibitor) resulted in a moderate (approximately 50%) increase in the blood concentration of this drug, and co-administration of this drug with cimetidine (moderate general enzyme inhibitor) resulted in a moderate (approximately 70%) increase in the blood concentration of this drug. Caution should be exercised when coadministering cimetidine and this drug, and dosage adjustment may be necessary.
When co-administering CYP2C19 inhibitors (e.g. fluoxetine, fluvoxamine, lansoprazole, ticlopidine) or cimetidine, caution should be exercised when administering the highest dose of this drug, and the dose of this drug may need to be reduced based on clinical judgment.
(2) Effect of this drug on the pharmacokinetics of other drugs
This drug is an inhibitor of CYP2D6. Caution should be exercised when administering this drug together with drugs that are primarily metabolized by the CYP2D6 enzyme. In particular, drugs with a narrow therapeutic index such as flecainide, propafenone, and metoprolol (when used in heart failure) or antidepressants such as desipramine, clomipramine, and nortryptyline, and risperidone, thioridazine, and For central nervous system drugs that are mainly metabolized by CYP2D6, such as antipsychotics such as haloperidol, caution should be exercised when co-administering this drug. Dosage adjustment may be necessary.
When coadministered with desipramine or metoprolol, which are CYP2D6 substrates, the blood concentrations of these two drugs increased two-fold.
In vitro tests showed that this drug may cause a weak inhibitory effect on CYP2C19, so caution should be exercised when co-administered with drugs metabolized by CYP2C19.
7. Administration to pregnant and lactating women
1) Pregnant women
There is no clinical data on the use of this drug in pregnant women.
In a reproductive toxicity test on rats, embryo-fetal toxicity (decreased fetal weight and mild ossification delay) was observed, but no increase in malformations was observed. The risk to humans is unknown. Therefore, for pregnant women, this drug is clearly necessary and should be administered only when the therapeutic benefits are judged to outweigh the risks.
Administration of SSRIs during the third trimester of pregnancy may have effects on the newborn, including mental and behavioral disorders in the newborn. Newborns of pregnant women who have taken this drug during the second half of pregnancy, especially the third trimester, need to be observed. If this medicine is administered until or just before birth, withdrawal effects may occur in the newborn.
The following symptoms may appear in newborns of pregnant women who take SSRIs/SNRIs until late in pregnancy: dyspnea, cyanosis, apnea, seizures, temperature instability, feeding difficulties, vomiting, hypoglycemia, hypertonia, hypotonia, hyperreflexia, tremor, agitation, irritability, lethargy, persistent crying, drowsiness, and difficulty sleeping. These symptoms may be due to serotonergic activity or withdrawal syndrome. In most cases, this occurs immediately after birth or within 24 hours.
Epidemiological studies have shown that the administration of SSRIs to pregnant women during pregnancy, especially in the second trimester, increases the risk of persistent pulmonary hypertension of the newborn (PPHN). The observed risk was approximately 5 cases per 1,000 pregnant women. In general, persistent neonatal pulmonary hypertension occurs at a rate of 1 to 2 cases per 1,000 pregnant women. Data from observational studies have reported an increased risk (less than 2-fold) of postpartum hemorrhage following exposure to SSRIs or SNRIs in the month before delivery.
2) Nursing mothers
This drug is expected to pass into breast milk. Therefore, this drug should not be administered to nursing mothers, or breastfeeding should be discontinued if this drug is administered.
3) Fertility
Animal studies have shown that citalopram may affect sperm quality. Human case reports involving some SSRIs have shown that the effects on sperm quality are reversible. Effects on human fertility have not yet been observed.
8. Administration to children (<18 years)
Because the safety and effectiveness of this drug have not been established for children and adolescents, it is recommended not to administer this drug (see warnings).
9. Administration to elderly people (>65 years old)
It is recommended that the initial dose be reduced to half the recommended dose and a lower maximum dose should be considered.
10. Effects on ability to drive and operate machines
This drug has not been shown to affect intellectual ability or psychomotor performance, but some psychoactive drugs may impair judgment or function. Patients should be aware of the potential risks this drug may have on their ability to drive and operate machinery.
11. Treatment in case of overdose
1) Toxicity
Clinical data on overdose of this drug is limited, and there were many cases of overdose combined with other drugs. In most cases, mild symptoms or no symptoms were reported. Fatal cases of overdose with this drug alone have been rarely reported. Most cases involved overdose of concomitant drugs. Overdosage of 400-800 mg of this drug alone did not cause any serious symptoms.
2) Symptoms
Symptoms of overdosage of this drug mainly include symptoms related to the central nervous system (from dizziness, tremors, and agitation to, in rare cases, serotonin syndrome, convulsions, and coma), gastrointestinal system (nausea/vomiting), cardiovascular system (hypotension, tachycardia, QT interval prolongation, arrhythmia), and electrolyte/fluid balance (hypokalemia, hyponatremia).
3) Treatment
There is no specific antidote for this drug. Secure the airway and maintain adequate oxygenation and breathing. Gastric lavage and the use of activated charcoal may be effective. If this drug is ingested orally, gastric lavage should be performed as quickly as possible. Monitor cardiac and vital signs along with general symptomatic supportive care.
ECG monitoring is recommended in cases of overdose in patients with congestive heart failure/bradycardia, patients taking concomitant medications that prolong the QT interval, or patients with altered metabolism (e.g., patients with hepatic impairment).
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
13. Others
1) Patients with CYP2C19 poor metabolizers:
For patients known to be CYP2C19 poor metabolizers, an initial dose of 5 mg per day is recommended for the first two weeks. Depending on the patient's response, the dosage can be increased up to 10 mg per day.
2) Patients with hepatic impairment:
In patients with mild or moderate hepatic impairment (Child-Pugh Criteria A and B), the half-life of this drug increased approximately two-fold, and drug exposure was approximately 60% higher than in patients with normal liver function.
3) Mechanism of action
Escitalopram binds with high affinity to the primary binding site and selectively inhibits serotonin reuptake. It also binds to the allosteric site of the serotonin transporter with an affinity that is 1000 times lower. Allosteric modulation of the serotonin transporter strengthens the binding of this drug to the primary binding site, resulting in a more complete serotonin reuptake inhibition effect.
Escitalopram has no or low affinity for many receptors, including 5-HT1A, 5-HT2, DA D1 and D2 receptors, α1-, α2-, and β-adrenergic receptors, histamine H1, muscarinic cholinergic, benzodiazepine, and narcotic receptors.
Therefore, inhibition of 5-HT reuptake is the only mechanism of action that explains the pharmacological and clinical effects of escitalopram.
Escitalopram is the S-enantiomer of racemic citalopram and is the enantiomer that exhibits therapeutic activity. Pharmacological studies have shown that the R-enantiomer is not an inert substance but rather interferes with the serotonin enhancing effect, which is the ultimate pharmacological property of the S-enantiomer.
4) Pharmacokinetic action
In a double-blind, placebo-controlled ECG study in healthy subjects, the QTc (Fridericia-correction) change from baseline was 4.3 msec at a 10 mg/day dose and 10.7 msec at a 30 mg/day dose.
5. How to save
Store in a light-proof, airtight container at room temperature (1∼30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle
7. Period of use
36 months from date of manufacture
- Active ingredient: Escitalopram oxalate (USP) ---- 12.77mg (10mg as escitalopram)
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: titanium oxide, magnesium stearate, low-substituted hydroxypropyl cellulose, colloidal silicon dioxide, polyethylene glycol 6000, hydroxypropyl cellulose, hypromellose 2910
2. Effectiveness
Treatment of major depressive disorder, panic disorder with or without agoraphobia, social anxiety disorder (social phobia), generalized anxiety disorder, and obsessive-compulsive disorder.
3. Dosage and dosage
The safety of doses exceeding 20 mg per day has not been established.
This medication is administered once a day in the morning or evening, regardless of meal.
1) Adult
(1) Major depressive disorder:
The usual dose is 10 mg once a day. Depending on the patient's response, the dose can be increased up to 20 mg per day. If you wish to increase the dose of this drug to 20mg, the increase must be done at intervals of at least 1 week.
Typically, it takes 2-4 weeks for antidepressants to take effect. Even after symptoms disappear, at least 6 months of drug treatment is necessary to ensure treatment effectiveness.
(2) Panic disorder with or without agoraphobia:
It is recommended to administer an initial dose of 5 mg per day for 1 week and then increase the dose to 10 mg per day. Depending on the patient's response, the dose can be increased up to 20 mg per day.
The maximum effect appears after about 3 months. The safety and effectiveness of long-term administration of this drug for more than 10 weeks in the treatment of panic disorder have not been systematically studied. Physicians should periodically reassess each patient to determine the need for ongoing treatment.
(3) Social anxiety disorder:
The usual dose is 10 mg once a day. Generally, 2-4 weeks are needed for symptoms to improve. After that, depending on the patient's response, the dose can be reduced to 5 mg per day or increased to a maximum of 20 mg per day.
Social anxiety disorder is a disease with a chronic course, and it is recommended to continue treatment for 12 weeks to ensure treatment effectiveness. Long-term treatment for responding patients has been studied for 6 months and is considered on an individual patient basis to prevent recurrence. The usefulness of long-term treatment should be reassessed regularly.
Social anxiety disorder is a well-defined diagnostic term for a specific disorder and should not be confused with excessive shyness. Drug treatment is administered only when social anxiety disorder significantly interferes with occupational and social activities. Comparison of pharmacological treatment with cognitive behavioral therapy has not been evaluated. Pharmacological treatment is one part of an overall treatment strategy.
(4) Generalized anxiety disorder:
The initial dose is 10 mg once a day. Depending on the patient's response, the dose may be increased up to 20 mg per day after administration for at least 1 week.
A long-term dosing trial was conducted in patients who responded to open administration for 12 weeks, administering 20 mg per day for at least 6 months. Physicians should periodically reassess the usefulness of long-term treatment with this drug for each patient.
(5) Obsessive-compulsive disorder:
The usual dose is 10 mg once a day. Depending on the patient's response, the dose can be increased to a maximum of 20 mg per day.
A long-term dosing trial was conducted in patients who responded to 16 weeks of open-label administration, administering 10 mg or 20 mg per day for at least 24 weeks. Since obsessive-compulsive disorder is a chronic disease, it must be administered for a sufficient period of time to ensure recovery of symptoms, and when this drug is administered long-term, the usefulness and dosage for each patient are regularly reevaluated.
2) Patients with renal impairment
No dose adjustment is necessary in patients with mild to moderate renal impairment. Caution should be exercised in patients with severe renal impairment (CLCR < 30 mL/min).
3) Patients with liver impairment
It is recommended to administer an initial dose of 5 mg per day for the first two weeks. Depending on the patient's response, the dosage can be increased up to 10 mg per day.
4) Discontinuation of administration
When discontinuing this medication, the dose should be tapered gradually over at least 1-2 weeks to avoid the possibility of withdrawal symptoms.
5) Related to switching to MAO inhibitors to treat mental illness
When discontinuing treatment with an MAO inhibitor for the treatment of mental illness and starting treatment with the same drug, there must be an interval of at least 14 days. Conversely, before starting treatment with an MAO inhibitor for the treatment of mental illness, at least 14 days must elapse after stopping the drug.
6) Other MAO inhibitors such as linezolid or methylene blue
Patients receiving linezolid or intravenous methylene blue products should not begin treatment with these products due to the increased risk of serotonin syndrome. Administration should be considered in patients requiring hospitalization, other interventional procedures, or treatment of more urgent psychiatric conditions.
There may be a need to urgently administer linezolid or intravenous methylene blue to patients who are already receiving this medication. If there is no alternative drug to linezolid or intravenous methylene blue and the benefit of treatment with linezolid or intravenous methylene blue is judged to outweigh the risk of serotonin syndrome in a specific patient, the medication should be discontinued immediately and linezolid or intravenous methylene blue should be administered immediately. The preparation can be administered. Patients should be monitored for symptoms of serotonin syndrome for 2 weeks after receiving linezolid or intravenous methylene blue products or 24 hours after the last dose, whichever comes first. Treatment with linezolid or intravenous methylene blue can be restarted 24 hours after the last dose.
The risk of administering methylene blue preparation non-intravenously (oral tablet or local injection) or injecting less than 1 mg/kg intravenously is not clear. Nevertheless, clinicians should be aware of the potential for emergent symptoms of serotonin syndrome with this use.
4. Precautions for use
1. Warning
Suicidality and antidepressants
Short-term studies of children, adolescents, and young adults (ages 18 to 24) with major depression or other psychiatric disorders have reported that antidepressants increase the risk of suicidal thoughts and behaviors (suicidality) compared to placebo. Physicians considering administering this drug or other antidepressants to children, adolescents, or young adults should always carefully consider whether the clinical need outweighs the risks. In short-term studies, antidepressants did not increase the risk of suicidality compared with placebo in adults over 25 years of age, and this risk was reduced with antidepressants compared to placebo in adults over 65 years of age. Depression and other psychiatric disorders themselves are associated with an increased risk of suicide. Patients of any age starting treatment with antidepressants should be appropriately monitored and carefully observed for worsening disease, suicidal tendencies, or changes in other abnormal behaviors such as hostility, aggression, or anger. The patient's family or guardian is also instructed to observe the patient carefully and contact the doctor if necessary. This drug is not approved for use in children and adolescents.
2. Do not administer to the following patients
1) Patients with hypersensitivity to escitalopram, the main ingredient of this drug, citalopram, a racemic form, or other components of this drug
2) Patients taking MAO inhibitors
Co-administration of this drug and MAO inhibitors for the treatment of mental illness or administration of MAO inhibitors within 14 days of discontinuing treatment with this drug is contraindicated because it increases the risk of serotonin syndrome. It is also contraindicated to administer this drug within 14 days of discontinuing treatment with MAO inhibitors for the treatment of mental illness. (Refer to section 4. Usage/Dosage and section 4. General precautions)
Initiating this drug in patients receiving MAO inhibitors such as linezolid or intravenous methylene blue preparations is also contraindicated due to the increased risk of serotonin syndrome (see Dosage and Administration section and Section 4. General Precautions).
3) Patients taking pimozide
4) Patients known to have congenital long QT syndrome or QT interval prolongation
5) Patients taking drugs that cause QT interval prolongation
3. Administer with caution to the following patients:
1) Patients with closed-angle glaucoma or patients with a history of glaucoma: Selective serotonin reuptake inhibitors (SSRIs), including this drug, may affect pupil size and cause mydriasis. This mydriatic effect narrows the canthus, increases intraocular pressure, and has the potential to cause closed-angle glaucoma, especially in patients with a predisposition to the disease. Therefore, patients with closed-angle glaucoma or patients with a history of glaucoma should use this drug with caution.
4. Adverse reactions
Adverse reactions occurred most frequently in the first 1-2 weeks after starting treatment with this drug, and generally decreased in intensity and frequency as treatment continued.
1) Adverse reactions known from SSRI drugs and observed in placebo-controlled clinical trials or post-marketing spontaneous reports of this drug are summarized by organ system and frequency in the table below.
Incidence rates are results obtained from clinical trials and are not placebo-corrected values. Incidence is defined as: very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥ 1/1000 to ≤ 1/100), rare (≥ 1/10000 to ≤ 1/1000), very rare (≤ 1/10000), or unknown (given data). (not measurable)
-Refer to attached document table-
2) The following are adverse reactions that occur with SSRI drugs: Increased suicidal tendencies in children, adolescents, and young adults (18-24 years old).
3) After marketing, ventricular arrhythmias including QT interval prolongation and polymorphic ventricular tachycardia (torsade de pointes) were reported, mainly in women, hypokalemia, and patients with existing QT interval prolongation or heart disease.
4) In an epidemiological study mainly targeting patients over 50 years of age, it was found that the risk of fracture increased in patients taking SSRIs and TCAs.
5) As a result of the post-marketing use results survey conducted in Korea for 4 years, the case rate of adverse reactions was reported to be 4.39% (60 cases/1,368 cases) regardless of causal relationship. ‘Nausea’ and ‘headache’ were the most common at 0.37% (5/1,368 people, 5 cases), ‘constipation’ and ‘dizziness’ at 0.29% (4/1,368 people, 4 cases), ‘dry mouth’, ‘abdominal pain’, ‘insomnia’, and ‘weight gain’ at 0.22% (3/1,368 people, 3 cases). ‘Fever’, ‘vomiting’, ‘indigestion’, ‘enteritis’, paresthesia’, ‘cough’, ‘sexual dysfunction’, ‘palpitations’ were 0.15% (2/1,368 people, 2 cases), other ‘diarrhea’, ‘paralysis’, ‘extrapyramidal disorder’, ‘migraine’, ‘reduced libido’, ‘lack of appetite’, ‘hallucinations’, ‘asthma’, ‘Difficult breathing’, ‘fracture’, ‘joint pain’, and ‘hypertension’ were each reported at 0.07% (1/1,368 people, 1 case). Among them, the rate of adverse drug reactions was 0.80% (11/1,368 people, 12 cases), 'nausea' at 0.22% (3/1,368 people, 3 cases), 'abdominal pain', 'drowsiness', and 'sexual dysfunction' at 0.15% each (2/1,368 people, 2 cases), and 'dizziness', 'reduced libido', ‘Weight gain’ was reported in 0.07% (1/1,368 people, 1 case).
Reported adverse reactions are classified by institution as follows.
① Gastrointestinal system: nausea, constipation, dry mouth, abdominal pain, vomiting, indigestion, enteritis, diarrhea
② Central and peripheral nervous system: headache, dizziness, paresthesia, paralysis, extrapyramidal disorder, migraine
③ Mental nervous system: drowsiness, insomnia, aggressive reactions, decreased libido, loss of appetite, hallucinations
④ Respiratory system: cough, asthma, difficulty breathing
⑤ Metabolic and nutritional abnormalities: weight gain
⑥ Systemic abnormalities: chest pain, fever
⑦ Musculoskeletal system: fractures, joint pain
⑧ Reproductive system (male): Sexual dysfunction
⑨ Cardiovascular system: palpitations, high blood pressure
6) In Korea, there were 88 adverse reactions reported separately from the post-marketing use results survey in 80 patients, including 15 nausea, 14 headaches, 9 dizziness, 8 drowsiness, 6 gastrointestinal disorders, 5 heartburn, 4 sedation, dry mouth, decreased libido, 3 each for decreased appetite, dry mouth, indigestion, sweating, frequent urination, sexual dysfunction, tremors, and weight gain. Two cases and one case each of abdominal discomfort, anxiety, insomnia, and visual hallucinations were reported. Among these, headache and frequent urination were unexpected side effects.
5. General precautions
The following precautions apply to all SSRI (Selective Serotonin Re-uptake Inhibitors) antidepressants.
1) Retrograde anxiety
Some patients with panic disorder may experience an increase in anxiety symptoms early in the initiation of antidepressant medication. This retrograde reaction usually disappears within the first two weeks of starting treatment. It is recommended to begin treatment with a lower initial dose to reduce the likelihood of developing anxiety.
2) Epileptic seizures
This drug should be discontinued in patients who experience epileptic seizures for the first time or if the number of seizures increases (in patients previously diagnosed with epilepsy). SSRIs should not be administered to patients with unstable epilepsy, and patients with controllable epilepsy should be closely observed after administration.
3) mania
SSRIs should be used with caution in patients with a history of mania/hypomania. In patients who are active in a manic state, administration of SSRIs should be discontinued.
Although not proven in controlled clinical trials, the use of antidepressants during a depressive episode in patients with bipolar disorder may precipitate mania or manic episodes. Therefore, before administering antidepressants, a detailed psychiatric history, including family history of suicide, bipolar disorder, or depression, should be checked to screen for the possibility of bipolar disorder.
4) Diabetes
When SSRIs are administered to patients with diabetes, glycemic control may be altered. Dosages of insulin and oral hypoglycemic agents may need to be adjusted.
5) Suicide
(1) Patients (adults, children) with major depression may experience worsening of depressive symptoms, suicidal thoughts and behaviors (suicidality), and abnormal behavioral changes even if they are taking antidepressants, until the disease shows significant improvement.
(2) Suicide is a known risk factor for depression and certain other psychiatric disorders, and these disorders are themselves the strongest predictors of suicide. However, there has been long-standing concern that antidepressants may lead to worsening of depressive symptoms and the development of suicidality in some patients during the early stages of treatment. A pooled analysis of placebo-controlled, short-term clinical trials of antidepressants (SSRIs and others) indicates that these drugs increase the risk of suicidal thoughts and behaviors (suicidality) in children, adolescents, and young adults (18-24 years) with major depression and other psychiatric disorders. In short-term studies, antidepressants did not increase the risk of suicidality compared with placebo in adults over 25 years of age. In adults over 65 years of age, this risk was reduced with antidepressants compared to placebo.
(3) A pooled analysis of placebo-controlled clinical trials in children and adolescents with major depression, obsessive-compulsive disorder, or other psychiatric disorders included a total of 24 short-term clinical trials of 9 antidepressants in more than 4,400 patients. The pooled analysis of placebo-controlled clinical trials in adults with major depression and other psychiatric disorders included a total of 295 short-term (median duration: 2 months) clinical trials of 11 antidepressants in more than 77,000 patients. Although there were significant differences in the risk of suicidality among drugs, there was a tendency for most all drugs studied to increase suicidality in young adults. There was a difference in the absolute risk of suicidality among different indications, with the highest incidence in major depression. However, the difference in risk (antidepressants vs. placebo) was relatively stable within age groups and between indications. This risk difference (difference between antidepressants and placebo in the number of suicidal tendencies per 1,000 treated patients) is shown in Table 1 below.
-Refer to attached document table-
(4) Suicide did not occur in any pediatric clinical trials. Suicides occurred in clinical trials in adults, but the numbers were not sufficient to draw any conclusions about the drug's effect on suicide. It is not known whether the risk of suicidality extends to long-term (i.e., more than several months) use of the drug. However, there is ample evidence from ongoing placebo-controlled clinical trials in adults with depression that the use of antidepressants may delay the recurrence of depression.
(5) It is unknown whether there is an increase in suicidal tendencies in adults or in patients taking long-term medication for several months or more; however, patients using antidepressants should be carefully monitored for the appearance and/or worsening of suicidal tendencies, self-harm, hostility, etc. during the first few months of administration or when changing the dose (increase or decrease).
(6) Patients using antidepressants may experience anxiety, agitation, panic disorder, insomnia, excitement, hostility, aggression, impulsivity, akathisia, hypomania, and mania. Although the correlation with these symptoms is unclear, caution should be exercised as they may be precursors to the development of suicidal tendencies. In addition, instruct family members and guardians to monitor these symptoms, suicidal tendencies, and clinical deterioration on a daily basis and notify the doctor immediately when symptoms appear.
(7) If depressive symptoms continue to worsen, suicidal tendencies appear, or symptoms that may be prodromal symptoms of suicidal tendencies (severe or sudden symptoms, symptoms not originally present in the patient) appear, discontinuation of this drug should be considered.
(8) When treating patients with other mental illnesses, the same precautions should be taken as when treating patients with major depression.
(9) Patients who have a history of suicide-related events or who have significant suicidal ideation before the start of administration are at greater risk of suicidal thoughts or attempts and should be carefully monitored during the administration period.
6) Akathisia/psychomotor anxiety
Administration of SSRIs/SNRIs is associated with the development of akathisia, a condition characterized by discomfort and anxiety and an inability to sit or stand still and an occasional need to move, which occurs within the first few weeks of administration. Increasing the dose in patients experiencing these symptoms may be harmful.
7) Hyponatremia
Hyponatremia, usually due to syndrome of abnormal secretion of antidiuretic hormone (SIADH), has been reported rarely with the use of SSRIs, and generally resolved with discontinuation of drug administration. Caution should be exercised in high-risk patients such as the elderly, patients with liver cirrhosis, or patients taking concomitant medications that may cause hyponatremia.
8) Bleeding
Skin bleeding abnormalities such as ecchymosis and purpura have been reported due to SSRIs. SSRIs or SNRIs may increase the risk of postpartum hemorrhage (see section ‘7. Administration to pregnant and lactating women’). Caution should be exercised, especially when administering SSRIs to patients taking oral anticoagulants or drugs known to affect platelet function (e.g. atypical antipsychotics, phenothiazines, most tricyclic antidepressants, acetosalicylic acid, nonsteroidal anti-inflammatory drugs (NSAIDs), ticlopidine, dipyridamole) or to patients with a known bleeding tendency.
9) Electroconvulsive Therapy
Caution should be exercised because experience with the combined treatment of SSRIs and electroconvulsive therapy is limited.
10) Cardiovascular disease
Because there is insufficient clinical experience, caution should be exercised in patients with coronary vascular disease.
11) Serotonin Syndrome
Serotonin-norepinephrine reuptake inhibitors (SNRIs) and serotonin selective reuptake inhibitors (SSRIs), including these agents, were administered alone, as well as other serotonergic drugs [triptan class drugs (sumatriptan, etc.), tricyclic antidepressants, opiates (fentanyl, etc.), lithium, tramadol, tryptophan, buspirone, and St. John's wort (St. John's wort). The development of potentially life-threatening serotonin syndrome has been reported when co-administered with drugs that inhibit serotonin metabolism (especially MAO inhibitors, both for the treatment of mental disorders, and other drugs such as linezolid and intravenous methylene blue).
Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, coma), autonomic instability (e.g., tachycardia, unstable blood pressure, dizziness, sweating, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, twitching, myoclonus, hyperreflexia, dyscoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome.
Co-administration of this agent and MAO inhibitors for the treatment of mental disorders is contraindicated. Additionally, treatment with MAO inhibitors such as linezolid or intravenous methylene blue should not be initiated in patients receiving MAO inhibitors. All postmarketing reports of methylene blue products for which route of administration information was provided include intravenous administration with a dose range of 1 mg/kg to 8 mg/kg. The reports do not include cases where methylene blue was administered by other routes of administration (such as tablets or local injection) or in low doses. Patients receiving this medication may need to start treatment with MAO inhibitors such as linezolid or intravenous methylene blue. This agent should be discontinued before starting MAO inhibitor treatment. (Refer to Dosage/Dosage section and section 2. Do not administer to the following patients)
If there is clinical benefit in co-administering this agent with other serotonergic drugs, for example triptans (e.g. sumatriptan), tricyclic antidepressants, opiates (e.g. fentanyl), lithium, tramadol, buspirone, tryptophan, and St. John's Wort, patients should be aware of the potentially increased risk of serotonin syndrome, especially during treatment initiation and when increasing doses. must be recognized
If the above-mentioned adverse reactions occur when co-administering this agent and serotonergic drugs, administration should be discontinued immediately and supportive symptomatic treatment should be initiated.
12) Withdrawal symptoms
Because there is a risk of experiencing withdrawal symptoms such as dizziness, sleep disturbance, and anxiety due to sudden discontinuation of administration, patients or guardians should not unilaterally stop taking this drug without consulting the prescribing doctor. When discontinuing treatment with this drug, it is recommended to gradually reduce the dose over several weeks or months.
Withdrawal symptoms due to discontinuation of treatment, especially sudden discontinuation of treatment, are frequent. In clinical trials, adverse reactions occurred when treatment was discontinued in approximately 25% of patients treated with this drug and in approximately 15% of patients treated with placebo.
The risk of withdrawal symptoms depends on several factors, including the duration and dose of treatment and the rate of dose reduction. The most commonly reported adverse reactions were dizziness, paresthesia (including paresthesia and electric shock sensations), sleep disturbances (insomnia and violent dreams), nervousness or anxiety, nausea and/or vomiting, tremors, confusion, sweating, headache, diarrhea, palpitations, agitation, irritability, and visual disturbances. In most cases, these symptoms are mild to moderate, but in some patients they can be severe.
These adverse reactions usually occur within the first few days after discontinuation of treatment, but very rarely have such symptoms been reported in patients who inadvertently missed a single dose. Generally, these symptoms are self-limited and usually resolve within 2 weeks, but in some patients they may be prolonged (2-3 months or longer).
13) QT interval prolongation
This drug has been shown to cause QT interval prolongation in a dose-dependent manner. After marketing, ventricular arrhythmias, including QT interval prolongation and polymorphic ventricular tachycardia (torsade de pointes), have been reported, mainly in women, hypokalemia, and patients with pre-existing QT interval prolongation or cardiac disease. Caution should be exercised in patients with significant bradycardia or patients who have recently had acute myocardial infarction or decompensated heart failure. Electrolyte imbalances such as hypokalemia and hypomagnesemia increase the risk of malignant arrhythmias and should be controlled prior to administration of this drug. If the patient is receiving treatment for cardiac disease, an ECG review should be considered before starting treatment with this drug. If there are signs of cardiac arrhythmia while taking this drug, treatment should be discontinued and an ECG should be performed.
14) Sexual dysfunction: Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) can cause symptoms of sexual dysfunction. Persistent sexual dysfunction with symptoms persisting even after discontinuation of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) has been reported.
6. Interaction
1) Pharmacokinetic interactions
(1) Contraindications for combined use:
① Non-selective, irreversible MAO inhibitor
In patients receiving SSRI drugs in combination with non-selective, irreversible MAO inhibitors or who recently stopped taking SSRIs and started taking MAO inhibitors, serious and sometimes fatal adverse reactions have been reported, including high fever, twitching, myoclonus, autonomic anxiety due to rapid fluctuations in vital signs, delirium, and changes in mental status, including extreme agitation that may progress to coma. Additionally, serotonin syndrome occurred in some patients.
Therefore, this drug and non-selective, irreversible MAO inhibitors should not be administered together. In the case of irreversible MAO inhibitors, start treatment 14 days after stopping treatment. Administration of non-selective, irreversible MAO inhibitors should be started at least 14 days after discontinuation of this drug.
② Reversible, non-selective MAO-inhibitor
Linezolid, an antibiotic, is a reversible non-selective MAO-inhibitor and should not be administered in combination with this drug. If co-administration is necessary, the lowest recommended dose should be administered and careful clinical observation should be conducted.
③ Reversible, selective MAO-A inhibitor
Due to the risk of serotonin syndrome, concurrent use of this drug with MAO-A inhibitors such as moclobemide is not recommended. If coadministration is necessary, administration should be initiated at the lowest recommended dose and careful clinical observation should be conducted.
④ Irreversible, selective MAO-B inhibitor
Concomitant use with selegiline should be used cautiously due to the risk of serotonin syndrome. A daily dose of 10 mg selegiline was safe when administered in combination with racemic citalopram.
⑤ Pimozide
In patients who were administered racemic citalopram 40 mg/day for 11 days, when single-dose pimozide 2 mg was co-administered, the AUC and Cmax of pimozide increased, although not consistently during the test period. Co-administration of pimozide and citalopram increased the QTc interval by approximately 10 msec. Due to the interaction seen with low doses of pimozide, this drug and pimozide should not be administered together.
⑥ Prolongation of QT interval
Although pharmacokinetic and pharmacodynamic studies have not been conducted on co-administration of this drug with other drugs that prolong the QT interval, additive effects of this drug cannot be excluded. Therefore, classes IA and III antiarrhythmic drugs, antipsychotics (e.g. phenothiazine derivatives, pimozide, haloperidol), tricyclic antidepressants, certain antibiotics (e.g. sparfloxacin, moxifloxacin, erythromycin IV, pentamidine, antimalarials (especially halofantrine)), certain antihistamines (astemizole, mizolastine), etc. Do not co-administer this drug with drugs that prolong the interval.
(2) Co-administration with caution
① Serotonergic drugs: Co-administration with serotonergic drugs (e.g. tramadol, sumatriptan and other triptan drugs) may cause serotonin syndrome.
② Drugs that lower the epileptic seizure threshold: SSRIs can lower the seizure threshold. Caution should be exercised when coadministering with other drugs that may lower the seizure threshold (antidepressants (tricyclics, SSRIs), neuroleptics (phenothiazines, butyrophenones, thioxanthenes), meproquine, bupropion, tramadol).
③ Lithium, tryptophan: There are reports that the effect of SSRIs is increased when administered in combination with lithium or tryptophan, so caution should be exercised when administering these drugs and SSRIs together.
④St. St. John's Wort: SSRIs and St. John's Wort. When coadministered with herbal preparations containing St. John's Wort (Hypericum perforatum), the occurrence of adverse reactions may increase.
⑤ Bleeding: If this drug and oral anticoagulants are administered together, the anticoagulant effect may be affected. In patients taking oral anticoagulants, the anticoagulant effect should be carefully monitored when starting or discontinuing treatment with this drug. Concomitant use with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase bleeding tendency.
⑥ Alcohol: No pharmacokinetic or pharmacodynamic interaction is expected between this drug and alcohol. However, like other psychoactive drugs, this drug is not recommended to be used together with alcohol.
2) Pharmacokinetic interactions
(1) The effect of other drugs on the pharmacokinetics of this drug
This drug is primarily metabolized by CYP2C19. CYP3A4 and CYP2D6 may also be involved in the metabolism of this drug, but to a very minor extent. A portion of the drug's main metabolite, demethylated escitalopram (S-DCT), appears to be re-metabolized by CYP2D6.
Co-administration of this drug with omeprazole (CYP2C19 inhibitor) resulted in a moderate (approximately 50%) increase in the blood concentration of this drug, and co-administration of this drug with cimetidine (moderate general enzyme inhibitor) resulted in a moderate (approximately 70%) increase in the blood concentration of this drug. Caution should be exercised when coadministering cimetidine and this drug, and dosage adjustment may be necessary.
When co-administering CYP2C19 inhibitors (e.g. fluoxetine, fluvoxamine, lansoprazole, ticlopidine) or cimetidine, caution should be exercised when administering the highest dose of this drug, and the dose of this drug may need to be reduced based on clinical judgment.
(2) Effect of this drug on the pharmacokinetics of other drugs
This drug is an inhibitor of CYP2D6. Caution should be exercised when administering this drug together with drugs that are primarily metabolized by the CYP2D6 enzyme. In particular, drugs with a narrow therapeutic index such as flecainide, propafenone, and metoprolol (when used in heart failure) or antidepressants such as desipramine, clomipramine, and nortryptyline, and risperidone, thioridazine, and For central nervous system drugs that are mainly metabolized by CYP2D6, such as antipsychotics such as haloperidol, caution should be exercised when co-administering this drug. Dosage adjustment may be necessary.
When coadministered with desipramine or metoprolol, which are CYP2D6 substrates, the blood concentrations of these two drugs increased two-fold.
In vitro tests showed that this drug may cause a weak inhibitory effect on CYP2C19, so caution should be exercised when co-administered with drugs metabolized by CYP2C19.
7. Administration to pregnant and lactating women
1) Pregnant women
There is no clinical data on the use of this drug in pregnant women.
In a reproductive toxicity test on rats, embryo-fetal toxicity (decreased fetal weight and mild ossification delay) was observed, but no increase in malformations was observed. The risk to humans is unknown. Therefore, for pregnant women, this drug is clearly necessary and should be administered only when the therapeutic benefits are judged to outweigh the risks.
Administration of SSRIs during the third trimester of pregnancy may have effects on the newborn, including mental and behavioral disorders in the newborn. Newborns of pregnant women who have taken this drug during the second half of pregnancy, especially the third trimester, need to be observed. If this medicine is administered until or just before birth, withdrawal effects may occur in the newborn.
The following symptoms may appear in newborns of pregnant women who take SSRIs/SNRIs until late in pregnancy: dyspnea, cyanosis, apnea, seizures, temperature instability, feeding difficulties, vomiting, hypoglycemia, hypertonia, hypotonia, hyperreflexia, tremor, agitation, irritability, lethargy, persistent crying, drowsiness, and difficulty sleeping. These symptoms may be due to serotonergic activity or withdrawal syndrome. In most cases, this occurs immediately after birth or within 24 hours.
Epidemiological studies have shown that the administration of SSRIs to pregnant women during pregnancy, especially in the second trimester, increases the risk of persistent pulmonary hypertension of the newborn (PPHN). The observed risk was approximately 5 cases per 1,000 pregnant women. In general, persistent neonatal pulmonary hypertension occurs at a rate of 1 to 2 cases per 1,000 pregnant women. Data from observational studies have reported an increased risk (less than 2-fold) of postpartum hemorrhage following exposure to SSRIs or SNRIs in the month before delivery.
2) Nursing mothers
This drug is expected to pass into breast milk. Therefore, this drug should not be administered to nursing mothers, or breastfeeding should be discontinued if this drug is administered.
3) Fertility
Animal studies have shown that citalopram may affect sperm quality. Human case reports involving some SSRIs have shown that the effects on sperm quality are reversible. Effects on human fertility have not yet been observed.
8. Administration to children (<18 years)
Because the safety and effectiveness of this drug have not been established for children and adolescents, it is recommended not to administer this drug (see warnings).
9. Administration to elderly people (>65 years old)
It is recommended that the initial dose be reduced to half the recommended dose and a lower maximum dose should be considered.
10. Effects on ability to drive and operate machines
This drug has not been shown to affect intellectual ability or psychomotor performance, but some psychoactive drugs may impair judgment or function. Patients should be aware of the potential risks this drug may have on their ability to drive and operate machinery.
11. Treatment in case of overdose
1) Toxicity
Clinical data on overdose of this drug is limited, and there were many cases of overdose combined with other drugs. In most cases, mild symptoms or no symptoms were reported. Fatal cases of overdose with this drug alone have been rarely reported. Most cases involved overdose of concomitant drugs. Overdosage of 400-800 mg of this drug alone did not cause any serious symptoms.
2) Symptoms
Symptoms of overdosage of this drug mainly include symptoms related to the central nervous system (from dizziness, tremors, and agitation to, in rare cases, serotonin syndrome, convulsions, and coma), gastrointestinal system (nausea/vomiting), cardiovascular system (hypotension, tachycardia, QT interval prolongation, arrhythmia), and electrolyte/fluid balance (hypokalemia, hyponatremia).
3) Treatment
There is no specific antidote for this drug. Secure the airway and maintain adequate oxygenation and breathing. Gastric lavage and the use of activated charcoal may be effective. If this drug is ingested orally, gastric lavage should be performed as quickly as possible. Monitor cardiac and vital signs along with general symptomatic supportive care.
ECG monitoring is recommended in cases of overdose in patients with congestive heart failure/bradycardia, patients taking concomitant medications that prolong the QT interval, or patients with altered metabolism (e.g., patients with hepatic impairment).
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
13. Others
1) Patients with CYP2C19 poor metabolizers:
For patients known to be CYP2C19 poor metabolizers, an initial dose of 5 mg per day is recommended for the first two weeks. Depending on the patient's response, the dosage can be increased up to 10 mg per day.
2) Patients with hepatic impairment:
In patients with mild or moderate hepatic impairment (Child-Pugh Criteria A and B), the half-life of this drug increased approximately two-fold, and drug exposure was approximately 60% higher than in patients with normal liver function.
3) Mechanism of action
Escitalopram binds with high affinity to the primary binding site and selectively inhibits serotonin reuptake. It also binds to the allosteric site of the serotonin transporter with an affinity that is 1000 times lower. Allosteric modulation of the serotonin transporter strengthens the binding of this drug to the primary binding site, resulting in a more complete serotonin reuptake inhibition effect.
Escitalopram has no or low affinity for many receptors, including 5-HT1A, 5-HT2, DA D1 and D2 receptors, α1-, α2-, and β-adrenergic receptors, histamine H1, muscarinic cholinergic, benzodiazepine, and narcotic receptors.
Therefore, inhibition of 5-HT reuptake is the only mechanism of action that explains the pharmacological and clinical effects of escitalopram.
Escitalopram is the S-enantiomer of racemic citalopram and is the enantiomer that exhibits therapeutic activity. Pharmacological studies have shown that the R-enantiomer is not an inert substance but rather interferes with the serotonin enhancing effect, which is the ultimate pharmacological property of the S-enantiomer.
4) Pharmacokinetic action
In a double-blind, placebo-controlled ECG study in healthy subjects, the QTc (Fridericia-correction) change from baseline was 4.3 msec at a 10 mg/day dose and 10.7 msec at a 30 mg/day dose.
5. How to save
Store in a light-proof, airtight container at room temperature (1∼30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle
7. Period of use
36 months from date of manufacture
Product Updates
Total 8items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 8 | Recipram Tab. | Precautions for use | 2024.02.12 | Escitalopram oxalate single agent (oral)_Unified adjustment (draft)_Change comparison table added.pdfFile under review |
| 7 | Recipram Tab. | Recipram tablets (precautions for use) | 2022.07.06 | Precautions for use_Recipram tablet (including change comparison table).pdfFile under review |
| 6 | Recipram Tab. | Recipram tablets (precautions for use) | 2017.08.08 | HWPPrecautions for use_Recipram Tablet.hwp |
| 5 | Recipram Tab. | Recipram tablets (precautions for use) | 0000.00.00 | HWPRecipram tablet_Precautions for use_Change instructions and preparation for change |
| 4 | Recipram Tab. | Recipram tablets (precautions for use) | 0000.00.00 | HWPEscitalopram single agent (oral) unification adjustment (draft).hwp |
| 3 | Recipram Tab. | Recipram tablets (dosage, precautions for use) | 2013.05.03 | HWPPermission change order_recipram tablet (correction).hwp |
| 2 | Recipram Tab. | Recipram tablets (dosage, precautions for use) | 2011.07.11 | HWPRecipram tablet usage dosage and precautions.hwp |
| 1 | Recipram Tab. | Recipram tablets (precautions for use) | 2009.10.06 | HWPChange in Recipram tablets (precautions for use) (2009.10.06).hwp |